Skip To Content

Study ID: Merck MK-3475-181 Keynote 181

Title:

A Randomized Open-label Phase III Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Paclitaxel or Docetaxel in Subjects with Advanced/Metastatic Squamous Cancer and Adenocarcinomas of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Jonathan Bleeker, MD,Amit Panwalkar, MD
Disease:
Esophagus
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.